Clinical Trials Interview June 2022, page-13

Morning HaveLots ... thanks for posting but what about all the patents that PAA have been granted and Purchased ,, Why has the IP Suite never been valued , most of these cost circa $700 USD a Year to keep live and registered.

The Company has NO Commercial Valuation,,, Look at what is happening at RAP, low on funds, Trials lagging along and now Pfizer has come in with a low ball offer and some cash ($4m)up front to assist the company from requiring a CR whilst they are in Negotiations ..

RAP is now in the process under SH demand that a Commercial Valuation is required , Business 101, know the value of what you own, know the value of what you are about to sell..simple..

Company started acquiring patents back in 2013

Assignment of intellectual property by NewSouth Innovations
https://stocknessmonster.com/announcements/paa.asx-XX658066/

PHARMAUST TO ACQUIRE RIGHTS TO THREE ONCOLOGY PRODUCT
PLATFORMS AND PARTNER WITH EXPERIENCED BIOTECHNOLOGY
COMMERCIALISERS
https://stocknessmonster.com/announcements/paa.asx-XX633597/

JOINT PATENT WITH JAPANESE COMPANY NOW PUBLISHED
https://stocknessmonster.com/announcements/paa.asx-XX633597/

IP EXCHANGE WITH UNSW CONSOLIDATES MPL PATENT POSITION

PharmAust secures core China patent
5 May 2017 – Perth, Australia:

PharmAust secures broad patent coverage for non-cancer
applications
17 May 2017
PharmAust secures core patent in Japan
6 June 2017 – Perth, A
PharmAust secures broad European patent for non-cancer
applications
8 June 2017 –
PharmAust secures core Europe patent
12 September 2017 – Perth
PharmAust secures broad patent in US for non-cancer
applications of Monepantel
10th October 2017
PharmAust secures patent in US for new portfolio of anticancer drugs
16 November 2017
5th March 2019 – Perth, Australia: PharmAust (ASX: PAA), a clinical-stage oncology
company, has received “Notices of Allowance” and “Notices to Grant” for a number of its
patent applications relating to MPL (monepantel), from various territories and jurisdictions
during 2018 and 2019. These patents pertain to both “Composition of Matter” in relation to
new MPL analogues (structurally similar entities to MPL) as well as to “Methods of Use” of
MPL and its analogues in cancer and other diseases. The catalogue of recent patents now
comprises:
Patent No./
Patent
Application No.
Field of Cover Status Country
Date of
Allowance/
Grant
2016204389 MPL for Treatment of Cancer Granted Australia 10/05/2018
2868120 MPL for Treatment of Cancer Allowed Canada 9/11/2018
201610041111.6 MPL Analogues for Treatment of
Cancer Allowed China 28/01/2019
2817286 MPL for Treatment of Cancer Granted Europe 6/06/2018
16162192.5 MPL Analogues for Treatment of
Cancer Allowed Europe 22/11/2018
2017-36116 MPL Analogues for Treatment of
Cancer Allowed Japan 21/01/2019
HK1205502 Compounds for the treatment of
mTOR pathway related diseases Granted Hong Kong 20/04/2018
6441219 Compounds for the treatment of
mTOR pathway related diseases Granted Japan 30/11/2018
10,053,422
Compounds for the treatment of
mTOR pathway related diseases
with Analogues
Granted United States of
America 21/08/2018
14781682.1
Anticancer agent comprising
aminoacetonitrile compound as
active ingredient (MPL Analogues)
Allowed Europe 14/12/2018
9,907,778
Anticancer agent comprising
aminoacetonitrile compound as
active ingredient (MPL Analogues)
Granted United States of
America 6/03/2018
15/878057
Anticancer agent comprising
aminoacetonitrile compound as
active ingredient (MPL Analogues)
Allowed United States of
America 15/01/

it goes on to 50 Patents acquired from Japan ......

so whats it all worth $$$$$$$$$$$$$$$$ ??? best we find out as SH you paid for these Valuable Patents..

The Company was last valued in 2016,,,, a lot has happened since then,
Dog Trials
Covid Trials
ONJF data MPL tested on 30 Human cancers positive effect on 28 Human Cancers..
You know the rest
WEHI positive data Biolabs 360 positive data , 9 months wait for Leiden data.

Since the WEHI confirmation of MPL vs Covid Sars the MC was 108m now $27m the more positive data PAA has gained the SP and value of the company has eroded ???

Time to Have an independent inform the market of PAA's value ,,,NZT